Dario Blood Glucose Monitoring System - Android Devices Altitude Evaluation Study
- Conditions
- Diabetes Mellitus
- Interventions
- Device: Blood Glucose Monitoring System Altitude Performance
- Registration Number
- NCT02916563
- Lead Sponsor
- LabStyle Innovations Ltd.
- Brief Summary
This study evaluates the performance of a blood glucose monitoring system at high altitudes (approximately 10,000 feet). The performance is assessed via a reference method for glucose analysis (Yellow Springs Instrument 2300 STAT Plus Glucose Analyzer).
- Detailed Description
This study will be a non-randomized study conducted to assess the accuracy and performance of the Dario Blood Glucose Monitoring System at an elevated altitude. 50 subjects will be enrolled in this study. Participation includes a 15-20 minute visit to the clinical site where they will be consented. The participant will then receive a fingerstick to obtain capillary blood used to test the performance of the BGMS and to obtain a comparative glucose measurement on the reference method, the Yellow Springs Instrument 2300 STAT Plus Glucose Analyzer.
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 50
- Able to speak and read English
- Pregnant
- Has any condition that the principle investigator believes may interfere in the subject's participation in the trial.
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- SINGLE_GROUP
- Arm && Interventions
Group Intervention Description Altitude Blood Glucose Monitoring System Altitude Performance Single arm study Blood Glucose Monitoring System Altitude Performance
- Primary Outcome Measures
Name Time Method Number of Successful Glucose Readings One day The success criterion for the performance of the Blood Glucose Monitoring System at high altitude (approximately 10,000 feet above sea level) means that 95% of the blood glucose readings fall within 15mg/dL of the YSI reference value (for reference values less than 75 mg/dL) and within 20% (for reference values greater than or equal to 75 mg/dL).
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (1)
Barbara Davis Center
🇺🇸Aurora, Colorado, United States